News
TAK
18.28
+0.99%
0.18
Takeda Advances Oral Crohn’s Disease Drug TAK-279 With Active Mid-Stage Trial
TipRanks · 12h ago
Bristol-Myers: Walking Blindfolded To A $30 Billion Patent Cliff
Seeking Alpha · 13h ago
Takeda granted Priority Review for oveporexton by FDA
TipRanks · 1d ago
FDA Grants Priority Review To Takeda's Oveporexton (TAK-861) For Narcolepsy Type 1, Targeting First-In-Class Orexin Therapy
Benzinga · 1d ago
TAKEDA PHARMACEUTICAL CO LTD - PDUFA TARGET ACTION DATE SET FOR Q3
Reuters · 1d ago
FDA Accepts Takeda's Oveporexton Application for Priority Review in Narcolepsy Type 1
Reuters · 1d ago
FDA nimmt Zulassungsantrag für Oveporexton von Takeda zur Prüfung an
Reuters · 1d ago
BRIEF-Takeda Pharmaceutical Co Ltd - U.S. FDA Accepts NDA And Grants Priority Review For Takeda's Oveporexton (Tak-861) As A Potential First-In-Class Therapy For Narcolepy Type 1
Reuters · 1d ago
U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Barchart · 2d ago
Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery
Benzinga · 2d ago
Takeda, Iambic ink AI drug discovery deal worth more than $1.7B
Seeking Alpha · 2d ago
Takeda deepens AI drug discovery push with $1.7 billion Iambic deal
Reuters · 2d ago
Weekly Report: what happened at TAK last week (0202-0206)?
Weekly Report · 2d ago
Takeda’s Elritercept Study Signals Long-Term Bet on MDS Anemia Innovation
TipRanks · 5d ago
Takeda’s Fazirsiran Phase 3 Liver Study Progresses, Strengthening Its Rare-Disease Pipeline Story
TipRanks · 5d ago
Takeda’s TAK-188 Trial: Early Immunotherapy Bet in Advanced Solid Tumors
TipRanks · 5d ago
Takeda Advances TAK-360 Sleep Disorder Trial, Signaling Growing Ambition in Orexin-Based Therapies
TipRanks · 5d ago
Takeda Advances Orexin-Mimicking Narcolepsy Drug TAK-360 Into Active Mid-Stage Testing
TipRanks · 5d ago
Cosmo Energy Holdings Announces Representative Director Change
Reuters · 5d ago
Japanese drugmakers slump after Trump unveils discount drug website
Reuters · 6d ago
More
Webull provides a variety of real-time TAK stock news. You can receive the latest news about Takeda Pharm through multiple platforms. This information may help you make smarter investment decisions.
About TAK
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.